EUCTR2005-002402-36-GB进行中（未招募）1 期
Multi-center, open-label trial to evaluate the safety and tolerability of Alpha-1 MP in subjects with Alpha-1-antitrypsin (a1AT) deficiency. STAMP: Safety and Tolerability of Alpha-1 MP - STAMP
Talecris Biotherapeutics0 个研究点目标入组 35 人开始时间: 2006年2月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Documented diagnosis of congenital Alpha1-antitrypsin deficiency with genotype being PiZZ, PiZ(null), Pi(null)(null), or At-risk” alleles as listed in Appendices 10.3. of the Study Protocol. The subject’s genotype must be documented by and/or verifiable through the Alpha-1 Antitrypsin Genetics Laboratory database located in Gainesville, Florida. If a subject's genotype is not documented and or verifiable by the Alpha-1 Antitrypsin Genetics Laboratory, the subject will be required, at screening to provide an additional blood sample (two 10-mL EDTA tubes)for analysis by the Alpha-1 Antitrypsin Genetics Laboratory. This analysis will include genotyping, and if the subject is treatment-naïve, a baseline serum Alpha-1 Proteinase Inhibitor level.
- •2. Documented Alpha-1 Proteinase Inhibitor serum levels <11uM prior to receiving any augmentation. For naïve subjects, the Alpha 1 Laboratory will also perform a screening Alpha1-Proteinase Inhibitor serum level to determine if the subjects meet this criteria. For those subjects entering the subject that are currently receiving augmentation therapy, historical data obtained at the time the subject was diagnosed with AAT deficiency will be used as verification of meeting this criteria.
- •3. Documented FEV1 between 20% - 80% of predicted value within last 6 months.
- •4. Either male or female age = 18 years
- •5. Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The following exclusion criteria must be evaluated at screening:
- •1. Diagnosis of liver cirrhosis;
- •2. Severe concomitant disease (e.g. congestive heart failure (NYHA III/IV), clinically significant pulmonary fibrosis, serious malignant disease);
- •3. Females who are pregnant, breast feeding, or if of child-bearing potential, unwilling to practice adequate contraception throughout the study;
- •4. Within the last month prior to study entry, participation in another clinical study if the subject received any investigational product during his/her participation in the investigational study.
- •5. History of anaphylaxis or severe systemic response to plasma-derived Alpha1-Proteinase Inhibitor or other blood product(s);
- •6. Use of systemic steroids within the 2 weeks prior to receiving study treatment (this does not include the use of inhaled steroids). Self-limited therapy with systemic steroids to treat an adverse event is not cause to discontinue or disrupt Alpha-1 PI therapy unless, in the opinion of the investigator, this action is warranted. The study’s Medical Monitor should be consulted if the subject requires frequent (>2) self-limited courses of systemic steroids or if long-term therapy is warranted during the subject’s participation in the study.
- •7. Known selective IgA deficiency
- •8. Mentally challenged adult subjects who cannot give independent informed consent;
- •9. Subjects who have had exacerbations of their disease within one month of trial entry;
研究者
相似试验
进行中（未招募）
不适用
Magnetic resonance imaging of the liver with Eovist/Primovist in children 0 to 2 months of ageMagnetic Resonance ImagingMedDRA version: 18.0Level: PTClassification code 10072304Term: Nuclear magnetic resonance imaging liverSystem Organ Class: 10022891 - InvestigationsEUCTR2012-000952-32-Outside-EU/EEABayer HealthCare AG10
招募中
3 期
A study to estimate the Safety and acceptability of Lumateperone as another treatment used together with the primary treatment in the Treatment of Patients with Major Depressive DisorderCTRI/2023/04/052094Intra-Cellular Therapies, Inc.
进行中（未招募）
1 期
A Study to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive DisorderMajor Depressive DisorderEUCTR2021-001172-41-BGIntra-Cellular Therapies, Inc.760
进行中（未招募）
1 期
A Study to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive DisorderMedDRA version: 20.0Level: LLTClassification code 10025458Term: Major depressive disorder, recurrent episode, moderate degreeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10081270Term: Major depressive disorderSystem Organ Class: 100000004873Major Depressive DisorderEUCTR2021-001172-41-FIIntra-Cellular Therapies, Inc.760
进行中（未招募）
1 期
A Study to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive DisorderMajor Depressive DisorderEUCTR2021-001172-41-SKIntra-Cellular Therapies, Inc.760